1B7/CD3 BsAb

N/A

Report date: 2026/03/19 17:15:59

Base Information

Drug Name1B7/CD3 BsAb

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-Cytokine receptor-like factor 2

TargetsT cell surface glycoprotein CD3Cytokine receptor-like factor 2

Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of Texas MD Anderson Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center

Inactive CompaniesN/A

Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A